Arca
Skip to content
Tools
Tools

Steroid 5-alpha-reductase

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on SRD5A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Abiraterone
  • Dutasteride

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        AbirateroneApprovedJohnson & JohnsonSmall moleculeInhibitorSteroid 5-alpha-reductase inhibitor173
        DutasterideApprovedWaylis TherapeuticsSmall moleculeInhibitorSteroid 5-alpha-reductase inhibitor13

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
        MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)AbirateronePhase 1 / Phase 2Not yet recruitingMerck Sharp & Dohme LLCNov 2, 2026
        Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation.DutasteridePhase 4Not yet recruitingMohamed Mahmoud DoghaNov 2, 2026
        Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerAbirateronePhase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research GroupOct 1, 2026
        A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current DrugsAbirateronePhase 2Not yet recruitingKokilaben Dhirubhai Ambani Hospital and Medical Research InstituteSep 24, 2026
        Abiraterone With Dalpiciclib in Salivary Gland CarcinomaAbirateronePhase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversitySep 11, 2026
        A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]AbirateronePhase 3RecruitingGlaxoSmithKlineSep 3, 2026
        A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.AbirateronePhase 2Not yet recruitingAnhui Medical UniversityAug 31, 2026
        Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerAbirateronePhase 3RecruitingUniversity College, LondonAug 7, 2026
        Study of XNW5004 Tablets in Advanced Prostate CancerAbirateronePhase 2Not yet recruitingEvopoint Biosciences Inc.Jul 28, 2026
        Assessment of Dutasteride Topical Solution in Male Androgenetic AlopeciaDutasteridePhase 1 / Phase 2Not yet recruitingMoogene Medi Co., LtdMar 24, 2026
        A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male SubjectsDutasteridePhase 1RecruitingAddpharma Inc.Mar 2, 2026
        Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)DutasterideNot applicableNot yet recruitingAssiut UniversityFeb 19, 2026
        Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder CancerDutasteridePhase 2RecruitingPaul TorenFeb 19, 2026
        Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEPDutasteride—RecruitingAnkara City Hospital BilkentFeb 18, 2026
        Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic HyperplasiaDutasteridePhase 1RecruitingUniversitas DiponegoroJul 15, 2025
        A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic AlopeciaDutasteridePhase 3RecruitingChong Kun Dang PharmaceuticalApr 8, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363075, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.